Access the full text.
Sign up today, get DeepDyve free for 14 days.
(CarrollTPGreeneCMO’ConnorCANolanAMO’NeillSJMcElvaneyNGEvidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiencyJ Immunol20101844538454620228200)
CarrollTPGreeneCMO’ConnorCANolanAMO’NeillSJMcElvaneyNGEvidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiencyJ Immunol20101844538454620228200CarrollTPGreeneCMO’ConnorCANolanAMO’NeillSJMcElvaneyNGEvidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiencyJ Immunol20101844538454620228200, CarrollTPGreeneCMO’ConnorCANolanAMO’NeillSJMcElvaneyNGEvidence for unfolded protein response activation in monocytes from individuals with alpha-1 antitrypsin deficiencyJ Immunol20101844538454620228200
A. Lockett, S. Kimani, G. Ddungu, S. Wrenger, R. Tuder, S. Janciauskiene, I. Petrache (2013)
a1-Antitrypsin Modulates Lung Endothelial Cell Inflammatory Responses to TNF-a
G. Pott, E. Chan, C. Dinarello, L. Shapiro (2009)
α‐1‐Antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole bloodJournal of Leukocyte Biology, 85
J. Carlson, Beverly Rogers, R. Sifers, M. Finegold, S. Clift, Franco DeMayo, D. Bullock, Savio Woo (1989)
Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice.The Journal of clinical investigation, 83 4
(JanciauskieneSMBalsRKoczullaRVogelmeierCKöhnleinTWelteTThe discovery of α1-antitrypsin and its role in health and diseaseRespir Med20111051129113921367592)
JanciauskieneSMBalsRKoczullaRVogelmeierCKöhnleinTWelteTThe discovery of α1-antitrypsin and its role in health and diseaseRespir Med20111051129113921367592JanciauskieneSMBalsRKoczullaRVogelmeierCKöhnleinTWelteTThe discovery of α1-antitrypsin and its role in health and diseaseRespir Med20111051129113921367592, JanciauskieneSMBalsRKoczullaRVogelmeierCKöhnleinTWelteTThe discovery of α1-antitrypsin and its role in health and diseaseRespir Med20111051129113921367592
(DirksenAPiitulainenEParrDGDengCWenckerMShakerSBet alExploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiencyEur Respir J2009331345135319196813)
DirksenAPiitulainenEParrDGDengCWenckerMShakerSBet alExploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiencyEur Respir J2009331345135319196813DirksenAPiitulainenEParrDGDengCWenckerMShakerSBet alExploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiencyEur Respir J2009331345135319196813, DirksenAPiitulainenEParrDGDengCWenckerMShakerSBet alExploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiencyEur Respir J2009331345135319196813
R. Stockley, M. Miravitlles, C. Vogelmeier (2013)
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approachOrphanet Journal of Rare Diseases, 8
(LockettADKimaniSDdunguGWrengerSTuderRMJanciauskieneSMet alα1-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-αAm J Respir Cell Mol Biol20134914315023526215)
LockettADKimaniSDdunguGWrengerSTuderRMJanciauskieneSMet alα1-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-αAm J Respir Cell Mol Biol20134914315023526215LockettADKimaniSDdunguGWrengerSTuderRMJanciauskieneSMet alα1-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-αAm J Respir Cell Mol Biol20134914315023526215, LockettADKimaniSDdunguGWrengerSTuderRMJanciauskieneSMet alα1-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-αAm J Respir Cell Mol Biol20134914315023526215
E. Chan, G. Pott, P. Silkoff, A. Ralston, C. Bryan, L. Shapiro (2012)
Alpha‐1‐antitrypsin inhibits nitric oxide productionJournal of Leukocyte Biology, 92
D. Parr, P. Guest, J. Reynolds, L. Dowson, R. Stockley (2007)
Prevalence and Impact of Bronchiectasis in α1-Antitrypsin DeficiencyAmerican Journal of Respiratory and Critical Care Medicine, 176
(IyerSSChengGRole of interleukin 10 transcriptional regulation in inflammation and autoimmune diseaseCrit Rev Immunol201232236322428854)
IyerSSChengGRole of interleukin 10 transcriptional regulation in inflammation and autoimmune diseaseCrit Rev Immunol201232236322428854IyerSSChengGRole of interleukin 10 transcriptional regulation in inflammation and autoimmune diseaseCrit Rev Immunol201232236322428854, IyerSSChengGRole of interleukin 10 transcriptional regulation in inflammation and autoimmune diseaseCrit Rev Immunol201232236322428854
(D’ArmientoJMScharfSMRothMDConnettJEGhioASternbergDet alEosinophil and T cell markers predict functional decline in COPD patientsRespir Res20091011319925666)
D’ArmientoJMScharfSMRothMDConnettJEGhioASternbergDet alEosinophil and T cell markers predict functional decline in COPD patientsRespir Res20091011319925666D’ArmientoJMScharfSMRothMDConnettJEGhioASternbergDet alEosinophil and T cell markers predict functional decline in COPD patientsRespir Res20091011319925666, D’ArmientoJMScharfSMRothMDConnettJEGhioASternbergDet alEosinophil and T cell markers predict functional decline in COPD patientsRespir Res20091011319925666
(BarkerAFIwata-MorganIOvesonLRousselRPharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiencyChest19971126076139315791)
BarkerAFIwata-MorganIOvesonLRousselRPharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiencyChest19971126076139315791BarkerAFIwata-MorganIOvesonLRousselRPharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiencyChest19971126076139315791, BarkerAFIwata-MorganIOvesonLRousselRPharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiencyChest19971126076139315791
Shuren Ma, Yong Lin, Jiangtao He, Farshid Rouhani, M. Brantly, G. Turino (2013)
Alpha-1 Antitrypsin Augmentation Therapy and Biomarkers of Elastin DegradationCOPD: Journal of Chronic Obstructive Pulmonary Disease, 10
S. Iyer, G. Cheng (2012)
Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.Critical reviews in immunology, 32 1
P. Gøtzsche, H. Johansen (2010)
Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease.The Cochrane database of systematic reviews, 7
S. Janciauskiene, R. Bals, R. Koczulla, C. Vogelmeier, T. Köhnlein, T. Welte (2011)
The discovery of α1-antitrypsin and its role in health and disease.Respiratory medicine, 105 8
A. Hill, D. Bayley, E. Campbell, S. Hill, R. Stockley (2000)
Airways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiency.The European respiratory journal, 15 5
K. Hurley, N. Lacey, C. O’Dwyer, D. Bergin, O. McElvaney, M. O'Brien, O. Mcelvaney, E. Reeves, N. McElvaney (2014)
Alpha-1 Antitrypsin Augmentation Therapy Corrects Accelerated Neutrophil Apoptosis in Deficient IndividualsThe Journal of Immunology, 193
Shuren Ma, S. Lieberman, G. Turino, Yong Lin (2003)
The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputumProceedings of the National Academy of Sciences of the United States of America, 100
(2016)
The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials.Chronic obstructive pulmonary diseases, 4 1
D. Huang, Brad Sherman, R. Lempicki (2008)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 4
A. Lockett, S. Kimani, G. Ddungu, S. Wrenger, R. Tuder, S. Janciauskiene, I. Petrache (2013)
α₁-Antitrypsin modulates lung endothelial cell inflammatory responses to TNF-α.American journal of respiratory cell and molecular biology, 49 1
(StollerJKAboussouanLSA review of α1-antitrypsin deficiencyAm J Respir Crit Care Med201218524625921960536)
StollerJKAboussouanLSA review of α1-antitrypsin deficiencyAm J Respir Crit Care Med201218524625921960536StollerJKAboussouanLSA review of α1-antitrypsin deficiencyAm J Respir Crit Care Med201218524625921960536, StollerJKAboussouanLSA review of α1-antitrypsin deficiencyAm J Respir Crit Care Med201218524625921960536
(CamposMAAlazemiSZhangGWannerASalatheMBaierHet alExacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapyRespir Med20091031532153919464158)
CamposMAAlazemiSZhangGWannerASalatheMBaierHet alExacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapyRespir Med20091031532153919464158CamposMAAlazemiSZhangGWannerASalatheMBaierHet alExacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapyRespir Med20091031532153919464158, CamposMAAlazemiSZhangGWannerASalatheMBaierHet alExacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapyRespir Med20091031532153919464158
G. Turino, Shuren Ma, J. Cantor, Yong Lin (2016)
Biomarkers in Alpha-1 Antitrypsin Deficiency Chronic Obstructive Pulmonary Disease.Annals of the American Thoracic Society, 13 Suppl 4
T. Köhnlein, S. Janciauskiene, T. Welte (2010)
Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiencyTherapeutic Advances in Respiratory Disease, 4
A. Barker, I. Iwata-Morgan, L. Oveson, R. Roussel (1997)
Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency.Chest, 112 3
Noel McElcaney, J. Stoller, A. Buist, U. Prakash, M. Brantly, M. Schluchter, R. Crystal (1997)
Baseline Characteristics of Enrollees in the National Heart, Lung and Blood Institute Registry of α1-Antitrypsin DeficiencyChest, 111
K. Chapman, R. Stockley, C. Dawkins, M. Wilkes, R. Navickis (2009)
Augmentation Therapy for α1 Antitrypsin Deficiency: A Meta-AnalysisCOPD: Journal of Chronic Obstructive Pulmonary Disease, 6
(JanciauskieneSWrengerSImmenschuhSOlejnickaBGreulichTWelteTet alThe multifaceted effects of alpha1-antitrypsin on neutrophil functionsFront Pharmacol2018934129719508)
JanciauskieneSWrengerSImmenschuhSOlejnickaBGreulichTWelteTet alThe multifaceted effects of alpha1-antitrypsin on neutrophil functionsFront Pharmacol2018934129719508JanciauskieneSWrengerSImmenschuhSOlejnickaBGreulichTWelteTet alThe multifaceted effects of alpha1-antitrypsin on neutrophil functionsFront Pharmacol2018934129719508, JanciauskieneSWrengerSImmenschuhSOlejnickaBGreulichTWelteTet alThe multifaceted effects of alpha1-antitrypsin on neutrophil functionsFront Pharmacol2018934129719508
P. Geraghty, E. Eden, M. Pillai, Michael Campos, N. McElvaney, R. Foronjy (2014)
α1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responses.American journal of respiratory and critical care medicine, 190 11
(StockleyRAHillATHillSLCampbellEJBronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiencyChest2000117Suppl 1291S293S10843958)
StockleyRAHillATHillSLCampbellEJBronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiencyChest2000117Suppl 1291S293S10843958StockleyRAHillATHillSLCampbellEJBronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiencyChest2000117Suppl 1291S293S10843958, StockleyRAHillATHillSLCampbellEJBronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiencyChest2000117Suppl 1291S293S10843958
J. Stoller, L. Aboussouan (2012)
A review of α1-antitrypsin deficiency.American journal of respiratory and critical care medicine, 185 3
(JonigkDAl-OmariMMaegelLMüllerMIzykowskiNHongJet alAnti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastaseProc Natl Acad Sci USA2013110150071501223975926)
JonigkDAl-OmariMMaegelLMüllerMIzykowskiNHongJet alAnti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastaseProc Natl Acad Sci USA2013110150071501223975926JonigkDAl-OmariMMaegelLMüllerMIzykowskiNHongJet alAnti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastaseProc Natl Acad Sci USA2013110150071501223975926, JonigkDAl-OmariMMaegelLMüllerMIzykowskiNHongJet alAnti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastaseProc Natl Acad Sci USA2013110150071501223975926
(LindénAHoshinoHLaanMAirway neutrophils and interleukin-17Eur Respir J20001597397710853869)
LindénAHoshinoHLaanMAirway neutrophils and interleukin-17Eur Respir J20001597397710853869LindénAHoshinoHLaanMAirway neutrophils and interleukin-17Eur Respir J20001597397710853869, LindénAHoshinoHLaanMAirway neutrophils and interleukin-17Eur Respir J20001597397710853869
R. Stockley, D. Bayley, I. Unsal, L. Dowson (2002)
The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.American journal of respiratory and critical care medicine, 165 11
Shuren Ma, Yong Lin, G. Turino (2007)
Measurements of desmosine and isodesmosine by mass spectrometry in COPD.Chest, 131 5
(GøtzschePCJohansenHKIntravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung diseaseCochrane Database Syst Rev20169CD00785127644166)
GøtzschePCJohansenHKIntravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung diseaseCochrane Database Syst Rev20169CD00785127644166GøtzschePCJohansenHKIntravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung diseaseCochrane Database Syst Rev20169CD00785127644166, GøtzschePCJohansenHKIntravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung diseaseCochrane Database Syst Rev20169CD00785127644166
(MaSLinYYHeJRouhaniFNBrantlyMTurinoGMAlpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradationCOPD20131047348123560990)
MaSLinYYHeJRouhaniFNBrantlyMTurinoGMAlpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradationCOPD20131047348123560990MaSLinYYHeJRouhaniFNBrantlyMTurinoGMAlpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradationCOPD20131047348123560990, MaSLinYYHeJRouhaniFNBrantlyMTurinoGMAlpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradationCOPD20131047348123560990
(BerginDAReevesEPMeleadyPHenryMMcElvaneyOJCarrollTPet alα-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8J Clin Invest20101204236425021060150)
BerginDAReevesEPMeleadyPHenryMMcElvaneyOJCarrollTPet alα-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8J Clin Invest20101204236425021060150BerginDAReevesEPMeleadyPHenryMMcElvaneyOJCarrollTPet alα-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8J Clin Invest20101204236425021060150, BerginDAReevesEPMeleadyPHenryMMcElvaneyOJCarrollTPet alα-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8J Clin Invest20101204236425021060150
A. Dirksen, E. Piitulainen, D. Parr, C. Deng, M. Wencker, S. Shaker, R. Stockley (2009)
Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiencyEuropean Respiratory Journal, 33
R. Stockley, R. Edgar, Sian Starkey, A. Turner (2018)
Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?Respiratory Research, 19
E. Lewis (2012)
Expanding the Clinical Indications for α1-Antitrypsin TherapyMolecular Medicine, 18
Michael Campos, Saleh Alazemi, Guoyan Zhang, A. Wanner, M. Salathe, H. Baier, R. Sandhaus (2009)
Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy.Respiratory medicine, 103 10
Bmc Cell Biology Concentration-dependent Effects of Native and Polymerised Α1-antitrypsin on Primary Human Monocytes, in Vitro
T. Carroll, C. Greene, C. O'Connor, Á. Nolan, S. O’Neill, N. McElvaney (2010)
Evidence for Unfolded Protein Response Activation in Monocytes from Individuals with α-1 Antitrypsin DeficiencyThe Journal of Immunology, 184
M. Wewers, M. Casolaro, S. Sellers, S. Swayze, K. McPhaul, J. Wittes, R. Crystal (1987)
Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema.The New England journal of medicine, 316 17
(MaSLinYYCantorJOChapmanKRSandhausRAFriesMet alThe effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trialsChronic Obstr Pulm Dis (Miami)20164344428848909)
MaSLinYYCantorJOChapmanKRSandhausRAFriesMet alThe effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trialsChronic Obstr Pulm Dis (Miami)20164344428848909MaSLinYYCantorJOChapmanKRSandhausRAFriesMet alThe effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trialsChronic Obstr Pulm Dis (Miami)20164344428848909, MaSLinYYCantorJOChapmanKRSandhausRAFriesMet alThe effect of alpha-1 proteinase inhibitor on biomarkers of elastin degradation in alpha-1 antitrypsin deficiency: an analysis of the RAPID/RAPID extension trialsChronic Obstr Pulm Dis (Miami)20164344428848909
(ChapmanKRStockleyRADawkinsCWilkesMMNavickisRJAugmentation therapy for alpha1 antitrypsin deficiency: a meta-analysisCOPD2009617718419811373)
ChapmanKRStockleyRADawkinsCWilkesMMNavickisRJAugmentation therapy for alpha1 antitrypsin deficiency: a meta-analysisCOPD2009617718419811373ChapmanKRStockleyRADawkinsCWilkesMMNavickisRJAugmentation therapy for alpha1 antitrypsin deficiency: a meta-analysisCOPD2009617718419811373, ChapmanKRStockleyRADawkinsCWilkesMMNavickisRJAugmentation therapy for alpha1 antitrypsin deficiency: a meta-analysisCOPD2009617718419811373
(HollanderCSitkauskieneBSakalauskasRWestinUJanciauskieneSMSerum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthmaRespir Med20071011947195317574828)
HollanderCSitkauskieneBSakalauskasRWestinUJanciauskieneSMSerum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthmaRespir Med20071011947195317574828HollanderCSitkauskieneBSakalauskasRWestinUJanciauskieneSMSerum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthmaRespir Med20071011947195317574828, HollanderCSitkauskieneBSakalauskasRWestinUJanciauskieneSMSerum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthmaRespir Med20071011947195317574828
R. Hubbard, S. Sellers, D. Czerski, L. Stephens, R. Crystal (1988)
Biochemical Efficacy and Safety of Monthly Augmentation Therapy for α1-Antitrypsin DeficiencyJAMA, 260
(PottGBChanEDDinarelloCAShapiroLAlpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole bloodJ Leukoc Biol20098588689519197072)
PottGBChanEDDinarelloCAShapiroLAlpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole bloodJ Leukoc Biol20098588689519197072PottGBChanEDDinarelloCAShapiroLAlpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole bloodJ Leukoc Biol20098588689519197072, PottGBChanEDDinarelloCAShapiroLAlpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole bloodJ Leukoc Biol20098588689519197072
I. Petrache, I. Fijalkowska, Terry Medler, Jarrett Skirball, P. Cruz, Lijie Zhen, H. Petrache, T. Flotte, R. Tuder (2006)
α-1 Antitrypsin Inhibits Caspase-3 Activity, Preventing Lung Endothelial Cell ApoptosisAmerican Journal of Pathology, 169
V. Bryant, C. Slade (2015)
Chemokines, their receptors and human disease: the good, the bad and the itchyImmunology and Cell Biology, 93
(CamposMGeraghtyPHoltGDonnaEMendesEEscobarLet alEffects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT deficiency (AATD)Eur Respir J201852PA571)
CamposMGeraghtyPHoltGDonnaEMendesEEscobarLet alEffects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT deficiency (AATD)Eur Respir J201852PA571CamposMGeraghtyPHoltGDonnaEMendesEEscobarLet alEffects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT deficiency (AATD)Eur Respir J201852PA571, CamposMGeraghtyPHoltGDonnaEMendesEEscobarLet alEffects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT deficiency (AATD)Eur Respir J201852PA571
(CarterRIMumfordRATreonzeKMFinkePEDaviesPSiQet alThe fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivoThorax20116668669121617168)
CarterRIMumfordRATreonzeKMFinkePEDaviesPSiQet alThe fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivoThorax20116668669121617168CarterRIMumfordRATreonzeKMFinkePEDaviesPSiQet alThe fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivoThorax20116668669121617168, CarterRIMumfordRATreonzeKMFinkePEDaviesPSiQet alThe fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivoThorax20116668669121617168
(WangZZhengTZhuZHomerRJRieseRJChapmanHAJret alInterferon gamma induction of pulmonary emphysema in the adult murine lungJ Exp Med20001921587160011104801)
WangZZhengTZhuZHomerRJRieseRJChapmanHAJret alInterferon gamma induction of pulmonary emphysema in the adult murine lungJ Exp Med20001921587160011104801WangZZhengTZhuZHomerRJRieseRJChapmanHAJret alInterferon gamma induction of pulmonary emphysema in the adult murine lungJ Exp Med20001921587160011104801, WangZZhengTZhuZHomerRJRieseRJChapmanHAJret alInterferon gamma induction of pulmonary emphysema in the adult murine lungJ Exp Med20001921587160011104801
(GeraghtyPEdenEPillaiMCamposMMcElvaneyNGForonjyRFα1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responsesAm J Respir Crit Care Med20141901229124225341065)
GeraghtyPEdenEPillaiMCamposMMcElvaneyNGForonjyRFα1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responsesAm J Respir Crit Care Med20141901229124225341065GeraghtyPEdenEPillaiMCamposMMcElvaneyNGForonjyRFα1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responsesAm J Respir Crit Care Med20141901229124225341065, GeraghtyPEdenEPillaiMCamposMMcElvaneyNGForonjyRFα1-Antitrypsin activates protein phosphatase 2A to counter lung inflammatory responsesAm J Respir Crit Care Med20141901229124225341065
(StockleyRAMiravitllesMVogelmeierCAlpha One International Registry (A.I.R.)Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approachOrphanet J Rare Dis2013814924063809)
StockleyRAMiravitllesMVogelmeierCAlpha One International Registry (A.I.R.)Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approachOrphanet J Rare Dis2013814924063809StockleyRAMiravitllesMVogelmeierCAlpha One International Registry (A.I.R.)Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approachOrphanet J Rare Dis2013814924063809, StockleyRAMiravitllesMVogelmeierCAlpha One International Registry (A.I.R.)Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approachOrphanet J Rare Dis2013814924063809
(ChanEDPottGBSilkoffPERalstonAHBryanCLShapiroLAlpha-1-antitrypsin inhibits nitric oxide productionJ Leukoc Biol2012921251126022975343)
ChanEDPottGBSilkoffPERalstonAHBryanCLShapiroLAlpha-1-antitrypsin inhibits nitric oxide productionJ Leukoc Biol2012921251126022975343ChanEDPottGBSilkoffPERalstonAHBryanCLShapiroLAlpha-1-antitrypsin inhibits nitric oxide productionJ Leukoc Biol2012921251126022975343, ChanEDPottGBSilkoffPERalstonAHBryanCLShapiroLAlpha-1-antitrypsin inhibits nitric oxide productionJ Leukoc Biol2012921251126022975343
(McElvaneyNGStollerJKBuistASPrakashUBBrantlyMLSchluchterMDet alBaseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency: Alpha 1-Antitrypsin Deficiency Registry Study GroupChest19971113944039041988)
McElvaneyNGStollerJKBuistASPrakashUBBrantlyMLSchluchterMDet alBaseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency: Alpha 1-Antitrypsin Deficiency Registry Study GroupChest19971113944039041988McElvaneyNGStollerJKBuistASPrakashUBBrantlyMLSchluchterMDet alBaseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency: Alpha 1-Antitrypsin Deficiency Registry Study GroupChest19971113944039041988, McElvaneyNGStollerJKBuistASPrakashUBBrantlyMLSchluchterMDet alBaseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency: Alpha 1-Antitrypsin Deficiency Registry Study GroupChest19971113944039041988
J. Barros-Tizón, M. Torres, I. Blanco, M. Martínez (2012)
Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapyTherapeutic Advances in Respiratory Disease, 6
J. Gadek, H. Klein, P. Holland, R. Crystal (1981)
Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects.The Journal of clinical investigation, 68 5
C. McCarthy, E. Reeves, N. McElvaney (2016)
The Role of Neutrophils in Alpha-1 Antitrypsin Deficiency.Annals of the American Thoracic Society, 13 Suppl 4
(Barros-TizónJCTorresMLBlancoIMartínezMTInvestigators of the rEXA Study GroupReduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapyTher Adv Respir Dis20126677822354900)
Barros-TizónJCTorresMLBlancoIMartínezMTInvestigators of the rEXA Study GroupReduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapyTher Adv Respir Dis20126677822354900Barros-TizónJCTorresMLBlancoIMartínezMTInvestigators of the rEXA Study GroupReduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapyTher Adv Respir Dis20126677822354900, Barros-TizónJCTorresMLBlancoIMartínezMTInvestigators of the rEXA Study GroupReduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapyTher Adv Respir Dis20126677822354900
(MaSLiebermanSTurinoGMLinYYThe detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputumProc Natl Acad Sci USA2003100129411294314563926)
MaSLiebermanSTurinoGMLinYYThe detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputumProc Natl Acad Sci USA2003100129411294314563926MaSLiebermanSTurinoGMLinYYThe detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputumProc Natl Acad Sci USA2003100129411294314563926, MaSLiebermanSTurinoGMLinYYThe detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputumProc Natl Acad Sci USA2003100129411294314563926
M. Campos, P. Geraghty, G. Holt, E. Donna, E. Mendes, L. Escobar, Landy Luna, R. Stockley (2018)
Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)Clinical Problems
(ParrDGGuestPGReynoldsJHDowsonLJStockleyRAPrevalence and impact of bronchiectasis in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med20071761215122117872489)
ParrDGGuestPGReynoldsJHDowsonLJStockleyRAPrevalence and impact of bronchiectasis in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med20071761215122117872489ParrDGGuestPGReynoldsJHDowsonLJStockleyRAPrevalence and impact of bronchiectasis in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med20071761215122117872489, ParrDGGuestPGReynoldsJHDowsonLJStockleyRAPrevalence and impact of bronchiectasis in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med20071761215122117872489
R. Hubbard, S. Sellers, D. Czerski, L. Stephens, R. Crystal (1988)
Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency.JAMA, 260 9
Michael Campos, F. Kueppers, J. Stocks, C. Strange, Junliang Chen, R. Griffin, L. Wang-Smith, M. Brantly (2013)
Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK)COPD: Journal of Chronic Obstructive Pulmonary Disease, 10
(McCarthyCReevesEPMcElvaneyNGThe role of neutrophils in alpha-1 antitrypsin deficiencyAnn Am Thorac Soc201613S297S30427564664)
McCarthyCReevesEPMcElvaneyNGThe role of neutrophils in alpha-1 antitrypsin deficiencyAnn Am Thorac Soc201613S297S30427564664McCarthyCReevesEPMcElvaneyNGThe role of neutrophils in alpha-1 antitrypsin deficiencyAnn Am Thorac Soc201613S297S30427564664, McCarthyCReevesEPMcElvaneyNGThe role of neutrophils in alpha-1 antitrypsin deficiencyAnn Am Thorac Soc201613S297S30427564664
(CarlsonJARogersBBSifersRNFinegoldMJCliftSMDeMayoFJet alAccumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic miceJ Clin Invest198983118311902784798)
CarlsonJARogersBBSifersRNFinegoldMJCliftSMDeMayoFJet alAccumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic miceJ Clin Invest198983118311902784798CarlsonJARogersBBSifersRNFinegoldMJCliftSMDeMayoFJet alAccumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic miceJ Clin Invest198983118311902784798, CarlsonJARogersBBSifersRNFinegoldMJCliftSMDeMayoFJet alAccumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic miceJ Clin Invest198983118311902784798
(KöhnleinTJanciauskieneSWelteTDiagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiencyTher Adv Respir Dis2010427928720660539)
KöhnleinTJanciauskieneSWelteTDiagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiencyTher Adv Respir Dis2010427928720660539KöhnleinTJanciauskieneSWelteTDiagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiencyTher Adv Respir Dis2010427928720660539, KöhnleinTJanciauskieneSWelteTDiagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiencyTher Adv Respir Dis2010427928720660539
D. Bergin, E. Reeves, P. Meleady, M. Henry, O. McElvaney, T. Carroll, C. Condron, S. Chotirmall, M. Clynes, S. O’Neill, N. McElvaney (2010)
α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8.The Journal of clinical investigation, 120 12
(CarterRIUngursMJMumfordRAStockleyRAAα-Val360: a marker of neutrophil elastase and COPD disease activityEur Respir J201341313822523359)
CarterRIUngursMJMumfordRAStockleyRAAα-Val360: a marker of neutrophil elastase and COPD disease activityEur Respir J201341313822523359CarterRIUngursMJMumfordRAStockleyRAAα-Val360: a marker of neutrophil elastase and COPD disease activityEur Respir J201341313822523359, CarterRIUngursMJMumfordRAStockleyRAAα-Val360: a marker of neutrophil elastase and COPD disease activityEur Respir J201341313822523359
(ShapiroLPottGBRalstonAHAlpha-1-antitrypsin inhibits human immunodeficiency virus type 1FASEB J20011511512211149899)
ShapiroLPottGBRalstonAHAlpha-1-antitrypsin inhibits human immunodeficiency virus type 1FASEB J20011511512211149899ShapiroLPottGBRalstonAHAlpha-1-antitrypsin inhibits human immunodeficiency virus type 1FASEB J20011511512211149899, ShapiroLPottGBRalstonAHAlpha-1-antitrypsin inhibits human immunodeficiency virus type 1FASEB J20011511512211149899
(GuyotNWartelleJMalleretLTodorovAADevouassouxGPachecoYet alUnopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysemaAm J Pathol20141842197221024929239)
GuyotNWartelleJMalleretLTodorovAADevouassouxGPachecoYet alUnopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysemaAm J Pathol20141842197221024929239GuyotNWartelleJMalleretLTodorovAADevouassouxGPachecoYet alUnopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysemaAm J Pathol20141842197221024929239, GuyotNWartelleJMalleretLTodorovAADevouassouxGPachecoYet alUnopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysemaAm J Pathol20141842197221024929239
(WewersMDCasolaroMASellersSESwayzeSCMcPhaulKMWittesJTet alReplacement therapy for alpha 1-antitrypsin deficiency associated with emphysemaN Engl J Med1987316105510623494198)
WewersMDCasolaroMASellersSESwayzeSCMcPhaulKMWittesJTet alReplacement therapy for alpha 1-antitrypsin deficiency associated with emphysemaN Engl J Med1987316105510623494198WewersMDCasolaroMASellersSESwayzeSCMcPhaulKMWittesJTet alReplacement therapy for alpha 1-antitrypsin deficiency associated with emphysemaN Engl J Med1987316105510623494198, WewersMDCasolaroMASellersSESwayzeSCMcPhaulKMWittesJTet alReplacement therapy for alpha 1-antitrypsin deficiency associated with emphysemaN Engl J Med1987316105510623494198
Anders Lindén, Hiroshi Hoshino, M. Laan (2000)
Airway neutrophils and interleukin-17.The European respiratory journal, 15 5
(NitaIHollanderCWestinUJanciauskieneSMProlastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine releaseRespir Res200561215683545)
NitaIHollanderCWestinUJanciauskieneSMProlastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine releaseRespir Res200561215683545NitaIHollanderCWestinUJanciauskieneSMProlastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine releaseRespir Res200561215683545, NitaIHollanderCWestinUJanciauskieneSMProlastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine releaseRespir Res200561215683545
(HurleyKLaceyNO’DwyerCABerginDAMcElvaneyOJO’BrienMEet alAlpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individualsJ Immunol20141933978399125217166)
HurleyKLaceyNO’DwyerCABerginDAMcElvaneyOJO’BrienMEet alAlpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individualsJ Immunol20141933978399125217166HurleyKLaceyNO’DwyerCABerginDAMcElvaneyOJO’BrienMEet alAlpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individualsJ Immunol20141933978399125217166, HurleyKLaceyNO’DwyerCABerginDAMcElvaneyOJO’BrienMEet alAlpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individualsJ Immunol20141933978399125217166
(BrantlyMLWittesJTVogelmeierCFHubbardRCFellsGACrystalRGUse of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypesChest19911007037081889260)
BrantlyMLWittesJTVogelmeierCFHubbardRCFellsGACrystalRGUse of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypesChest19911007037081889260BrantlyMLWittesJTVogelmeierCFHubbardRCFellsGACrystalRGUse of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypesChest19911007037081889260, BrantlyMLWittesJTVogelmeierCFHubbardRCFellsGACrystalRGUse of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypesChest19911007037081889260
I. Nita, Camilla Hollander, U. Westin, S. Janciauskiene (2005)
Prolastin, a pharmaceutical preparation of purified human α1-antitrypsin, blocks endotoxin-mediated cytokine releaseRespiratory Research, 6
Camilla Hollander, B. Šitkauskienė, R. Sakalauskas, U. Westin, S. Janciauskiene (2007)
Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma.Respiratory medicine, 101 9
(AldonyteRJanssonLJanciauskieneSConcentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitroBMC Cell Biol200451115050036)
AldonyteRJanssonLJanciauskieneSConcentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitroBMC Cell Biol200451115050036AldonyteRJanssonLJanciauskieneSConcentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitroBMC Cell Biol200451115050036, AldonyteRJanssonLJanciauskieneSConcentration-dependent effects of native and polymerised alpha1-antitrypsin on primary human monocytes, in vitroBMC Cell Biol200451115050036
R. Carter, M. Ungurs, R. Mumford, R. Stockley (2012)
A&agr;-Val360: a marker of neutrophil elastase and COPD disease activityEuropean Respiratory Journal, 41
(StockleyRAEdgarRGStarkeySTurnerAMHealth status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?Respir Res20181913730029692)
StockleyRAEdgarRGStarkeySTurnerAMHealth status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?Respir Res20181913730029692StockleyRAEdgarRGStarkeySTurnerAMHealth status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?Respir Res20181913730029692, StockleyRAEdgarRGStarkeySTurnerAMHealth status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?Respir Res20181913730029692
(CarterRIUngursMJPillaiAMumfordRAStockleyRAThe relationship of the fibrinogen cleavage biomarker Aα-Val360 with disease severity and activity in α1-antitrypsin deficiencyChest201514838238825569856)
CarterRIUngursMJPillaiAMumfordRAStockleyRAThe relationship of the fibrinogen cleavage biomarker Aα-Val360 with disease severity and activity in α1-antitrypsin deficiencyChest201514838238825569856CarterRIUngursMJPillaiAMumfordRAStockleyRAThe relationship of the fibrinogen cleavage biomarker Aα-Val360 with disease severity and activity in α1-antitrypsin deficiencyChest201514838238825569856, CarterRIUngursMJPillaiAMumfordRAStockleyRAThe relationship of the fibrinogen cleavage biomarker Aα-Val360 with disease severity and activity in α1-antitrypsin deficiencyChest201514838238825569856
(LewisECExpanding the clinical indications for α(1)-antitrypsin therapyMol Med20121895797022634722)
LewisECExpanding the clinical indications for α(1)-antitrypsin therapyMol Med20121895797022634722LewisECExpanding the clinical indications for α(1)-antitrypsin therapyMol Med20121895797022634722, LewisECExpanding the clinical indications for α(1)-antitrypsin therapyMol Med20121895797022634722
(McElvaneyNGBurdonJHolmesMGlanvilleAWarkPAThompsonPJet alRAPID Extension Trial GroupLong-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)Lancet Respir Med20175516027916480)
McElvaneyNGBurdonJHolmesMGlanvilleAWarkPAThompsonPJet alRAPID Extension Trial GroupLong-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)Lancet Respir Med20175516027916480McElvaneyNGBurdonJHolmesMGlanvilleAWarkPAThompsonPJet alRAPID Extension Trial GroupLong-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)Lancet Respir Med20175516027916480, McElvaneyNGBurdonJHolmesMGlanvilleAWarkPAThompsonPJet alRAPID Extension Trial GroupLong-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)Lancet Respir Med20175516027916480
N. McElvaney, J. Stoller, A. Buist, U. Prakash, M. Brantly, M. Schluchter, R. Crystal (1997)
Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group.Chest, 111 2
(GadekJEKleinHGHollandPVCrystalRGReplacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjectsJ Clin Invest198168115811657028785)
GadekJEKleinHGHollandPVCrystalRGReplacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjectsJ Clin Invest198168115811657028785GadekJEKleinHGHollandPVCrystalRGReplacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjectsJ Clin Invest198168115811657028785, GadekJEKleinHGHollandPVCrystalRGReplacement therapy of alpha 1-antitrypsin deficiency: reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjectsJ Clin Invest198168115811657028785
I. Petrache, I. Fijalkowska, Terry Medler, Jarrett Skirball, P. Cruz, Lijie Zhen, H. Petrache, T. Flotte, R. Tuder (2006)
alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis.The American journal of pathology, 169 4
H. Tilg, E. Vannier, G. Vachino, Charles Dinardlo, J. Mier (1993)
Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cellsThe Journal of Experimental Medicine, 178
(HuangWShermanBTLempickiRASystematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNat Protoc20094445719131956)
HuangWShermanBTLempickiRASystematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNat Protoc20094445719131956HuangWShermanBTLempickiRASystematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNat Protoc20094445719131956, HuangWShermanBTLempickiRASystematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNat Protoc20094445719131956
(StockleyRABayleyDLUnsalIDowsonLJThe effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med20021651494149812045122)
StockleyRABayleyDLUnsalIDowsonLJThe effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med20021651494149812045122StockleyRABayleyDLUnsalIDowsonLJThe effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med20021651494149812045122, StockleyRABayleyDLUnsalIDowsonLJThe effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med20021651494149812045122
D. Parr, P. Guest, J. Reynolds, L. Dowson, R. Stockley (2007)
Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency.American journal of respiratory and critical care medicine, 176 12
(TilgHVannierEVachinoGDinarelloCAMierJWAntiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cellsJ Exp Med1993178162916367693853)
TilgHVannierEVachinoGDinarelloCAMierJWAntiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cellsJ Exp Med1993178162916367693853TilgHVannierEVachinoGDinarelloCAMierJWAntiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cellsJ Exp Med1993178162916367693853, TilgHVannierEVachinoGDinarelloCAMierJWAntiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cellsJ Exp Med1993178162916367693853
(PetracheIFijalkowskaIMedlerTRSkirballJCruzPZhenLet alalpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosisAm J Pathol20061691155116617003475)
PetracheIFijalkowskaIMedlerTRSkirballJCruzPZhenLet alalpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosisAm J Pathol20061691155116617003475PetracheIFijalkowskaIMedlerTRSkirballJCruzPZhenLet alalpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosisAm J Pathol20061691155116617003475, PetracheIFijalkowskaIMedlerTRSkirballJCruzPZhenLet alalpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosisAm J Pathol20061691155116617003475
R. Carter, R. Mumford, K. Treonze, P. Finke, P. Davies, Qian Si, J. Humes, A. Dirksen, E. Piitulainen, Ali Ahmad, R. Stockley (2011)
The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivoThorax, 66
(CamposMGeraghtyPHoltGDonnaEMendesEEscobarLAet alThe biological effects of double dose augmentation therapy for subjects with alpha-1 antitrypsin deficiency [abstract]Am J Respir Crit Care Med2017195A6315)
CamposMGeraghtyPHoltGDonnaEMendesEEscobarLAet alThe biological effects of double dose augmentation therapy for subjects with alpha-1 antitrypsin deficiency [abstract]Am J Respir Crit Care Med2017195A6315CamposMGeraghtyPHoltGDonnaEMendesEEscobarLAet alThe biological effects of double dose augmentation therapy for subjects with alpha-1 antitrypsin deficiency [abstract]Am J Respir Crit Care Med2017195A6315, CamposMGeraghtyPHoltGDonnaEMendesEEscobarLAet alThe biological effects of double dose augmentation therapy for subjects with alpha-1 antitrypsin deficiency [abstract]Am J Respir Crit Care Med2017195A6315
(HillATBayleyDLCampbellEJHillSLStockleyRAAirways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiencyEur Respir J20001588689010853853)
HillATBayleyDLCampbellEJHillSLStockleyRAAirways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiencyEur Respir J20001588689010853853HillATBayleyDLCampbellEJHillSLStockleyRAAirways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiencyEur Respir J20001588689010853853, HillATBayleyDLCampbellEJHillSLStockleyRAAirways inflammation in chronic bronchitis: the effects of smoking and alpha1-antitrypsin deficiencyEur Respir J20001588689010853853
L. Shapiro, Gregory POTT, Annemarie RALSTON (2001)
Alpha‐1‐antitrypsin inhibits human immunodeficiency virus type 1The FASEB Journal, 15
M. Brantly, J. Wittes, C. Vogelmeier, R. Hubbard, G. Fells, R. Crystal (1991)
Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes.Chest, 100 3
S. Janciauskiene, S. Wrenger, S. Immenschuh, B. Olejnicka, T. Greulich, T. Welte, J. Chorostowska-Wynimko (2018)
The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil FunctionsFrontiers in Pharmacology, 9
(BryantVLSladeCAChemokines, their receptors and human disease: the good, the bad and the itchyImmunol Cell Biol20159336437125895814)
BryantVLSladeCAChemokines, their receptors and human disease: the good, the bad and the itchyImmunol Cell Biol20159336437125895814BryantVLSladeCAChemokines, their receptors and human disease: the good, the bad and the itchyImmunol Cell Biol20159336437125895814, BryantVLSladeCAChemokines, their receptors and human disease: the good, the bad and the itchyImmunol Cell Biol20159336437125895814
R. Carter, M. Ungurs, A. Pillai, R. Mumford, R. Stockley (2015)
The Relationship of the Fibrinogen Cleavage Biomarker Aα-Val360 With Disease Severity and Activity in α1-Antitrypsin Deficiency.Chest, 148 2
(CamposMAKueppersFStocksJMStrangeCChenJGriffinRet alSafety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK)COPD20131068769523862647)
CamposMAKueppersFStocksJMStrangeCChenJGriffinRet alSafety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK)COPD20131068769523862647CamposMAKueppersFStocksJMStrangeCChenJGriffinRet alSafety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK)COPD20131068769523862647, CamposMAKueppersFStocksJMStrangeCChenJGriffinRet alSafety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK)COPD20131068769523862647
(ChapmanKRBurdonJGPiitulainenESandhausRASeersholmNStocksJMet alRAPID Trial Study GroupIntravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trialLancet201538636036826026936)
ChapmanKRBurdonJGPiitulainenESandhausRASeersholmNStocksJMet alRAPID Trial Study GroupIntravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trialLancet201538636036826026936ChapmanKRBurdonJGPiitulainenESandhausRASeersholmNStocksJMet alRAPID Trial Study GroupIntravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trialLancet201538636036826026936, ChapmanKRBurdonJGPiitulainenESandhausRASeersholmNStocksJMet alRAPID Trial Study GroupIntravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trialLancet201538636036826026936
R Stockley, Adam Hill, Susan Hill, Edward Campbell (2000)
Bronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiency.Chest, 117 5 Suppl 1
N. McElvaney, J. Burdon, M. Holmes, A. Glanville, P. Wark, Philip Thompson, P. Hernandez, J. Chlumsky, H. Teschler, J. Ficker, N. Seersholm, A. Altraja, R. Mäkitaro, J. Chorostowska-Wynimko, M. Sanak, P. Stoicescu, E. Piitulainen, O. Vit, M. Wencker, M. Tortorici, Michael Fries, J. Edelman, K. Chapman (2017)
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).The Lancet. Respiratory medicine, 5 1
K. Chapman, J. Burdon, E. Piitulainen, R. Sandhaus, N. Seersholm, J. Stocks, B. Stoel, Liping Huang, Zhenling Yao, J. Edelman, N. McElvaney (2015)
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trialThe Lancet, 386
Zhongde Wang, T. Zheng, Zhou Zhu, R. Homer, R. Riese, H. Chapman, S. Shapiro, J. Elias (2000)
Interferon γ Induction of Pulmonary Emphysema in the Adult Murine LungThe Journal of Experimental Medicine, 192
D. Jonigk, Mariam Al-Omari, L. Maegel, Meike Müller, N. Izykowski, Jaewoo Hong, Kwangwon Hong, Soohyun Kim, M. Dorsch, R. Mahadeva, F. Laenger, H. Kreipe, A. Braun, G. Shahaf, E. Lewis, T. Welte, C. Dinarello, S. Janciauskiene (2013)
Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastaseProceedings of the National Academy of Sciences, 110
N. Guyot, Julien Wartelle, L. Malleret, A. Todorov, G. Devouassoux, Y. Pacheco, D. Jenne, A. Belaaouaj (2014)
Unopposed cathepsin G, neutrophil elastase, and proteinase 3 cause severe lung damage and emphysema.The American journal of pathology, 184 8
(TurinoGMMaSCantorJOLinYYBiomarkers in alpha-1 antitrypsin deficiency chronic obstructive pulmonary diseaseAnn Am Thorac Soc201613S336S34027564670)
TurinoGMMaSCantorJOLinYYBiomarkers in alpha-1 antitrypsin deficiency chronic obstructive pulmonary diseaseAnn Am Thorac Soc201613S336S34027564670TurinoGMMaSCantorJOLinYYBiomarkers in alpha-1 antitrypsin deficiency chronic obstructive pulmonary diseaseAnn Am Thorac Soc201613S336S34027564670, TurinoGMMaSCantorJOLinYYBiomarkers in alpha-1 antitrypsin deficiency chronic obstructive pulmonary diseaseAnn Am Thorac Soc201613S336S34027564670
J. D’Armiento, S. Scharf, M. Roth, J. Connett, A. Ghio, D. Sternberg, J. Goldin, T. Louis, J. Mao, G. O'Connor, J. Ramsdell, A. Ries, N. Schluger, F. Sciurba, M. Skeans, H. Voelker, R. Walter, C. Wendt, G. Weinmann, R. Wise, R. Foronjy (2009)
Eosinophil and T cell markers predict functional decline in COPD patientsRespiratory Research, 10
(MorrisonHMKrampsJABurnettDStockleyRALung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profileClin Sci (Lond)1987723733812434283)
MorrisonHMKrampsJABurnettDStockleyRALung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profileClin Sci (Lond)1987723733812434283MorrisonHMKrampsJABurnettDStockleyRALung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profileClin Sci (Lond)1987723733812434283, MorrisonHMKrampsJABurnettDStockleyRALung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profileClin Sci (Lond)1987723733812434283
H. Morrison, J. Kramps, D. Burnett, R. Stockley (1987)
Lung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile.Clinical science, 72 3
A. Barker, I. Iwata-Morgan, L. Oveson, R. Roussel (1997)
Clinical Investigations: COPDPharmacokinetic Study of α1-Antitrypsin Infusion in α1-Antitrypsin DeficiencyChest, 112
(HubbardRCSellersSCzerskiDStephensLCrystalRGBiochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiencyJAMA1988260125912643261353)
HubbardRCSellersSCzerskiDStephensLCrystalRGBiochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiencyJAMA1988260125912643261353HubbardRCSellersSCzerskiDStephensLCrystalRGBiochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiencyJAMA1988260125912643261353, HubbardRCSellersSCzerskiDStephensLCrystalRGBiochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiencyJAMA1988260125912643261353
(MaSLinYYTurinoGMMeasurements of desmosine and isodesmosine by mass spectrometry in COPDChest20071311363137117494786)
MaSLinYYTurinoGMMeasurements of desmosine and isodesmosine by mass spectrometry in COPDChest20071311363137117494786MaSLinYYTurinoGMMeasurements of desmosine and isodesmosine by mass spectrometry in COPDChest20071311363137117494786, MaSLinYYTurinoGMMeasurements of desmosine and isodesmosine by mass spectrometry in COPDChest20071311363137117494786
Mark Brantly, Janet Wittes, Claus Vogelmeier, R. Hubbard, G. Fells, R. Crystal (1991)
Use of a Highly Purified α1-Antitrypsin Standard to Establish Ranges for the Common Normal and Deficient α1-Antitrypsin PhenotypesChest, 100
Rationale: Augmentation therapy with intravenous AAT (alpha-1 antitrypsin) is the only specific therapy for individuals with pulmonary disease from AAT deficiency (AATD). The recommended standard dose (SD; 60 mg/kg/wk) elevates AAT trough serum levels to around 50% of normal; however, outside of slowing emphysema progression, its effects in other clinical outcomes have not been rigorously proven.Objectives: To evaluate the biological effects of normalizing AAT trough levels with double-dose (DD) therapy (120 mg/kg/wk) in subjects with AATD already receiving SD therapy.Methods: Clinically stable subjects were evaluated after 4 weeks of SD therapy, followed by 4 weeks of DD therapy, and 4 weeks after return to SD therapy. At the end of each phase, BAL fluid (BALF) and plasma samples were obtained.Measurements and Main Results: DD therapy increased trough AAT levels to normal and, compared with SD therapy, reduced serine protease activity in BALF (elastase and cathepsin G), plasma elastase footprint (Aα-Val360), and markers of elastin degradation (desmosine/isodesmosine) in BALF. DD therapy also further downregulated BALF ILs and cytokines including Jak-STAT (Janus kinases–signal transducer and activator of transcription proteins), TNFα (tumor necrosis factor-α), and T-cell receptor signaling pathways, cytokines involved in macrophage migration, eosinophil recruitment, humoral and adaptive immunity, neutrophil activation, and cachexia. On restarting SD after DD treatment, a possible carryover effect was seen for several biological markers.Conclusions: Subjects with AATD on SD augmentation therapy still exhibit inflammation, protease activity, and elastin degradation that can be further improved by normalizing AAT levels. Higher AAT dosing than currently recommended may lead to enhanced clinical benefits and should be explored further.Clinical trial registered with www.clinicaltrials.gov (NCT 01669421).
American Journal of Respiratory and Critical Care Medicine – Pubmed Central
Published: Aug 1, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.